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We report the experiences of 5 patients taking bedaquiline 
with delamanid in combination: 1 patient was cured; 3 cul-
ture converted, with 2 continuing and 1 changing therapy; 
and 1 died from respiratory insufficiency. For 2 patients, QT-
interval prolongation but no arrhythmias occurred. Use of 
this therapy is justified for patients with limited options.
According to the World Health Organization (WHO), 480,000 multidrug-resistant (MDR) tuberculosis (TB) 
and 100,000 rifampin-resistant TB cases, and 250,000 
deaths attributable to these 2 conditions, occurred glob-
ally in 2015 (1). About 10% of the bacteria isolates from 
MDR TB cases met the criteria for extensively drug-resis-
tant (XDR) TB (resistance to any fluoroquinolone and >1 
second-line injectable drugs) (1,2).
MDR TB and XDR TB treatments are of long dura-
tion, expensive, and complicated by a high rate of adverse 
events, making determining an effective drug regimen of-
ten difficult, considering that a minimum of 4 active drugs 
are required according to WHO recommendations (1–4). In 
this regard, bedaquiline (5,6) and delamanid (7) might be 
crucial for designing effective treatment regimens.
Although these drugs are increasingly used in combi-
nation in complicated cases (8–11), public health officials 
are concerned that the co-administration of bedaquiline and 
delamanid could increase the occurrence of adverse events, 
particularly for QT prolongation, which might occur more 
often when these drugs are combined with other TB drugs 
that prolong the QT interval (i.e., fluoroquinolones and clo-
fazimine). Only 2 reports describe the co-administration of 
these drugs (8–11). As of July 2017, the WHO does not 
recommend their combined use, given the lack of evidence 
regarding their safety (4).
MDR TB reference centers belonging to the Interna-
tional Bedaquiline Study Group (25 centers located in 15 
countries in Africa, Asia, Western and Eastern Europe, 
Oceania, and South America working within the frame-
work of the European Respiratory Society, the Asociación 
Latinoamericana de Tórax, and the Brazilian Society col-
laborative projects) (12) performed a large study investi-
gating safety, tolerability, and effectiveness of bedaquiline-
containing regimens for MDR and XDR TB patients treated 
through and not through national TB programs. However, 
no information on co-administration of bedaquiline and 
delamanid was included. We conducted a retrospective and 
observational subanalysis of patients from the Internation-
al Bedaquiline Study Group study who were undergoing 
treatment with bedaquiline and delamanid.
The Study
We consecutively enrolled patients ≥15 years of age from 
the International Bedaquiline Study Group study who un-
derwent treatment during January 1, 2008–August 30, 
2016, on the basis of their exposure to both bedaquiline and 
delamanid during the intensive and/or continuation phase 
of the study. Bedaquiline was administered at the recom-
mended dosage of 400 mg/d for 14 days and then 200 mg 
3×/wk with delamanid at 200 mg/d. We obtained ethics ap-
proval for this retrospective research from the coordinating 
center and each clinical center that enrolled the patients as 
required by law; patients and attending physicians signed 
consent forms agreeing to participate.
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 Bedaquiline and Delamanid for Pulmonary XDR TB
The following were considered adverse events: an 
absolute QT interval corrected with Fridericia’s formu-
la (QTcF) prolongation of >500 ms; a QTcF increase of 
>60 ms over the baseline reading; cardiac arrest; ventricu-
lar tachycardia or atrial fibrillation; syncope; and events 
suggestive of arrhythmia, dizziness, seizures, and palpi-
tations. To assess severity, we used the Common Termi-
nology Criteria for Adverse Events version 4.0 (https://
evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_
QuickReference_8.5x11.pdf).
Of the 428 patients with culture-confirmed MDR TB 
who were treated with bedaquiline, 5 received combined 
treatment with delamanid. Considering the long half-life 
of bedaquiline (>5 months), 2 additional patients could 
have also been considered to have combined treatment; 
they were treated with delamanid shortly after bedaqui-
line (5–6). On April 28, 2017, we obtained information 
on the patients’ last follow-up from the physicians man-
aging their care, and this information was updated in the 
study database.
Bedaquiline and delamanid were given concurrently to 
5 patients with pulmonary XDR TB who lived in Russia 
(2), India (2), or the Netherlands (1) (Table 1). Four were 
women and 1 was a man; patients were 17–43 years of age. 
All were HIV negative, and 2 were recreational drug users. 
All had previously been treated with TB drugs (range 1–8 
treatments) for >30 days; 4 patients had drug treatment fail-
ures, and 1 had a relapse. Chest radiographs indicated that 
3 patients had extensive bilateral cavities, 1 had bilateral 
lesions (without cavities), and 1 had monolateral cavitary 
lung disease. All patients were sputum-smear and culture 
positive for mycobacteria and had been potentially infec-
tious for a mean of 65 weeks.
The resistance patterns of the isolated Mycobacteri-
um tuberculosis strains were extensive, ranging from 5 to 
10 drugs (Table 1). Salvage regimens were designed for 
each patient on the basis of their unique resistance pat-
terns, which lead to their treatments including bedaquiline 
and delamanid (Table 2). All regimens included another 
QT-prolonging drug in addition to bedaquiline and dela-
manid: moxifloxacin (patients 1 and 3) or clofazimine 
(patients 2, 4, and 5). Patient exposure to bedaquiline was 
155–427 days, for a total duration of TB treatment of 16–
46 months. The total duration of hospital admission was 
256–1,140 days. 
As of April 28, 2017, patient 3 had been declared 
cured; patients 2, 4, and 5 were continuing therapy, al-
though patient 2 was receiving a different drug regimen. 
Patient 1 had received 4 months of salvage therapy, but 
treatment failed, and she died from respiratory insufficien-
cy. Patient 2 switched therapies because bedaquiline and 
delamanid had been already administered for a fixed period 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 10, October 2017 1719
 








sex Risk factor 
No. 
treatments 
>30 d, case 
category 
Weeks 
ss+ and c+ 
before 


















Bdq + Dlm (at 
end of study) 





S, H, R, E, Z, 
Fq, PAS, Km, 












S, H, R, E, Z, 






1, failure 62 54 (76) 36 887 Cm, Z, Mfx, 
Trd, Pto, 
PAS 
H, R, E, Fq, Km 
4 Azerbaijan/
Russia 
17/F None 1, failure 20 53 (51) 16 256 Z, Cm, Lfx, 
Pto, Cs, 
PAS 
H, R, E, Z, Km, 
Amk, Cm, Fq 
5 Tibet/India 39/F None 2, relapse 52 65 (60) 18 1,140 H, R, Z, E, 
Hd H, Mfx, 
Km, PAS, 
Lzd, Pto 
R, Km, Amk, 
Cm, Fq, Eto, 
PAS, Lzd, 
Hd H, Hd Mfx 
*All patients were sputum smear and culture positive. Amk, amikacin; Amx/Clv, amoxicillin/clavulanate; Bdq, bedaquiline; c+, culture positive; Cfz, 
clofazimine; Clr, clarithromycin; Cm, capreomycin; Cs, cycloserine; Dlm, delamanid; E, ethambutol; Eto, ethionamide; Fq, fluoroquinolone; H, isoniazid; 
Hd, high dose; Km, kanamycin; Lfx, levofloxacin; Lzd, linezolid; MDR TB, multidrug-resistant tuberculosis; Mfx, moxifloxacin; Mpm, meropenem; NA, not 
available; PAS, para-aminosalicylic acid; Pt, patient; Pto, prothionamide; R, rifampin; Rfb, rifabutin; S, streptomycin; ss+, sputum smear positive; TB, 
tuberculosis; Trd, terizidone; Z, pyrazinamide. 
 
DISPATCHES
of 168 days as recommended by WHO. With the excep-
tion of patient 1, who remained sputum-smear and culture 
positive, the other 4 patients’ sputum smears converted to 
negative after 18–435 days, and cultures converted after 
28–218 days.
As recommended, all patients underwent QTcF-inter-
val monitoring at baseline, at 2 weeks, and then monthly 
(4), even though no patient had a history of heart problems 
or electrocardiogram abnormalities. A QTc interval >500 
ms is considered a risk factor for fatal arrhythmia; when 
this sign is found in patients, clinicians should either stop 
treatment with >1 QTc-prolonging drugs and start vera-
pimil or watch and closely monitor. The baseline QTcF 
intervals were <500 (range 340–449) ms for all patients. 
Patients 1, 2, and 3 did not report adverse events for beda-
quiline or delamanid, and their QTcF intervals remained 
below the threshold. Patient 5’s QTcF interval reached 
520 ms at week 16, which required a dose adjustment and 
the introduction of verapamil (9–11). Patient 5’s treatment 
continued without further problems; she continued improv-
ing clinically, with improved chest radiograph findings 
and continuously negative sputum smears and cultures. 
Patient 4 had a QTcF interval of 509 ms twice. Each time 
the treating physician practiced closer clinical observation 
with more frequent electrocardiogram monitoring, and her 
QTcF interval normalized spontaneously without changes 
in treatment.
Conclusions
We report that of 5 patients receiving bedaquiline and dela-
manid in combination 2 had potentially life-threatening 
QTcF prolongation. The clinical centers took the necessary 
precautions and acted promptly to manage the problem, and 
no arrhythmias occurred (9–11). When patients received 
bedaquiline, delamanid, and another QTc-prolonging 
agent, clinically significant cardiac events and permanent 
discontinuation of bedaquiline and delamanid did not oc-
cur. For patient 1, additional resistance to ethionamide 
and linezolid was detected in a drug susceptibility test in 
the final phase. This treatment failure highlights that great 
care is needed when deciding drug regimens; the resistance 
threshold of both repurposed and new drugs still needs to 
be determined. Although these data are preliminary and 
more work is needed, the findings from this cohort sug-
gest that providing bedaquiline and delamanid in combina-
tion as part of therapy against XDR TB is justified when 
clinical options are limited. Two ongoing randomized con-
trolled trials (ClinicalTrials.gov nos. NCT02583048 and 
NCT02754765) have experimental arms containing these 
drugs in combination, so additional datasets will be avail-
able in the future.
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